O	0	10	Prevention	Prevention	NN	B-NP
O	11	13	of	of	IN	B-PP
B-Cancer	14	21	hepatic	hepatic	JJ	B-NP
I-Cancer	22	27	tumor	tumor	NN	I-NP
O	28	38	metastases	metastasis	NNS	I-NP
O	39	41	in	in	IN	B-PP
O	42	46	rats	rat	NNS	B-NP
O	47	51	with	with	IN	B-PP
O	52	58	herpes	herpes	NN	B-NP
O	59	64	viral	viral	JJ	I-NP
O	65	73	vaccines	vaccine	NNS	I-NP
O	74	77	and	and	CC	O
O	78	83	gamma	gamma	SYM	O
O	83	84	-	-	HYPH	O
O	84	94	interferon	interferon	NN	B-NP
O	94	95	.	.	.	O

O	97	105	Previous	Previous	JJ	B-NP
O	106	113	studies	study	NNS	I-NP
O	114	120	showed	show	VBD	B-VP
O	121	125	that	that	IN	B-SBAR
O	126	134	gammaIFN	gammaIFN	NN	B-NP
O	135	144	decreases	decrease	VBZ	B-VP
B-Cancer	145	155	metastatic	metastatic	JJ	B-NP
I-Cancer	156	163	hepatic	hepatic	JJ	I-NP
I-Cancer	164	169	tumor	tumor	NN	I-NP
O	170	176	growth	growth	NN	I-NP
O	177	179	by	by	IN	B-PP
O	180	191	stimulating	stimulate	VBG	B-VP
B-Cell	192	199	Kupffer	Kupffer	NNP	B-NP
I-Cell	200	205	cells	cell	NNS	I-NP
O	206	207	(	(	(	O
B-Cell	207	209	KC	KC	NN	B-NP
O	209	210	)	)	)	O
O	210	211	.	.	.	O

O	212	215	The	The	DT	B-NP
O	216	223	present	present	JJ	I-NP
O	224	231	studies	study	NNS	I-NP
O	232	239	examine	examine	VBP	B-VP
O	240	247	whether	whether	IN	B-SBAR
B-Cell	248	258	lymphocyte	lymphocyte	NN	B-NP
O	259	270	stimulation	stimulation	NN	I-NP
O	271	274	via	via	IN	B-PP
B-Cell	275	280	cells	cell	NNS	B-NP
O	281	291	engineered	engineer	VBN	B-VP
O	292	294	to	to	TO	B-VP
O	295	302	secrete	secrete	VB	I-VP
O	303	305	GM	GM	NNP	B-NP
O	305	306	-	-	HYPH	B-NP
O	306	309	CSF	CSF	NN	I-NP
O	310	312	or	or	CC	I-NP
O	313	315	IL	IL	NN	I-NP
O	315	316	-	-	HYPH	O
O	316	317	2	2	CD	B-NP
O	318	327	decreases	decrease	VBZ	B-VP
B-Cancer	328	335	hepatic	hepatic	JJ	B-NP
I-Cancer	336	341	tumor	tumor	NN	I-NP
O	342	348	growth	growth	NN	I-NP
O	348	349	,	,	,	O
O	350	353	and	and	CC	O
O	354	361	whether	whether	IN	B-SBAR
O	362	373	stimulation	stimulation	NN	B-NP
O	374	376	of	of	IN	B-PP
O	377	381	both	both	DT	B-NP
B-Cell	382	393	macrophages	macrophage	NNS	I-NP
O	394	397	and	and	CC	I-NP
B-Cell	398	409	lymphocytes	lymphocyte	NNS	I-NP
O	410	412	is	be	VBZ	B-VP
O	413	417	more	more	RBR	B-ADJP
O	418	427	effective	effective	JJ	I-ADJP
O	428	432	than	than	IN	B-PP
O	433	439	either	either	DT	B-NP
O	440	452	individually	individually	RB	B-ADVP
O	452	453	.	.	.	O

O	454	458	Rats	Rat	NNS	B-NP
O	459	463	were	be	VBD	B-VP
O	464	473	immunized	immunize	VBN	I-VP
O	474	478	with	with	IN	B-PP
O	479	489	irradiated	irradiated	JJ	B-NP
B-Cell	490	498	hepatoma	hepatoma	NN	I-NP
I-Cell	499	504	cells	cell	NNS	I-NP
O	505	515	transduced	transduce	VBN	B-VP
O	516	518	by	by	IN	B-PP
O	519	525	herpes	herpes	NN	B-NP
O	526	531	viral	viral	JJ	I-NP
O	532	540	amplicon	amplicon	NN	I-NP
O	541	548	vectors	vector	NNS	I-NP
O	549	559	containing	contain	VBG	B-VP
O	560	563	the	the	DT	B-NP
O	564	569	genes	gene	NNS	I-NP
O	570	573	for	for	IN	B-PP
O	574	576	GM	GM	NNP	B-NP
O	576	577	-	-	HYPH	B-NP
O	577	580	CSF	CSF	NNP	I-NP
O	580	581	,	,	,	O
O	582	584	IL	IL	NNP	B-NP
O	584	585	-	-	HYPH	I-NP
O	585	586	2	2	CD	I-NP
O	587	589	or	or	CC	I-NP
O	590	594	LacZ	LacZ	NN	I-NP
O	594	595	.	.	.	O

O	596	598	On	On	IN	B-PP
O	599	602	day	day	NN	B-NP
O	603	605	18	18	CD	I-NP
O	605	606	,	,	,	O
O	607	611	half	half	NN	B-NP
O	612	614	of	of	IN	B-PP
O	615	619	each	each	DT	B-NP
O	620	625	group	group	NN	I-NP
O	626	629	was	be	VBD	B-VP
O	630	637	treated	treat	VBN	I-VP
O	638	642	with	with	IN	B-PP
O	643	644	5	5	CD	B-NP
O	645	646	x	x	NN	I-NP
O	647	649	10	10	CD	I-NP
O	649	650	(	(	(	O
O	650	651	4	4	CD	B-NP
O	651	652	)	)	)	O
O	653	654	U	U	NN	B-NP
O	655	663	gammaIFN	gammaIFN	NN	I-NP
O	663	664	,	,	,	O
O	665	667	or	or	CC	O
O	668	674	saline	saline	NN	B-NP
B-Immaterial_anatomical_entity	675	692	intraperitoneally	intraperitoneally	RB	B-ADVP
O	693	696	for	for	IN	B-PP
O	697	698	3	3	CD	B-NP
O	699	700	d	d	NN	I-NP
O	700	701	.	.	.	O

O	702	704	On	On	IN	B-PP
O	705	708	day	day	NN	B-NP
O	709	711	21	21	CD	I-NP
O	711	712	,	,	,	O
O	713	716	all	all	DT	B-NP
O	717	721	rats	rat	NNS	I-NP
O	722	730	received	receive	VBD	B-VP
O	731	732	5	5	CD	B-NP
O	733	734	x	x	NN	I-NP
O	735	737	10	10	CD	I-NP
O	737	738	(	(	(	O
O	738	739	5	5	CD	B-NP
O	739	740	)	)	)	O
B-Cell	741	749	hepatoma	hepatoma	NN	B-NP
I-Cell	750	755	cells	cell	NNS	I-NP
B-Immaterial_anatomical_entity	756	772	intrasplenically	intrasplenically	RB	B-ADVP
O	772	773	.	.	.	O

O	774	776	On	On	IN	B-PP
O	777	780	day	day	NN	B-NP
O	781	783	41	41	CD	I-NP
O	783	784	,	,	,	O
O	785	789	rats	rat	NNS	B-NP
O	790	794	were	be	VBD	B-VP
O	795	801	killed	kill	VBN	I-VP
O	802	805	and	and	CC	O
B-Cancer	806	811	tumor	tumor	NN	B-NP
I-Cancer	812	819	nodules	nodule	NNS	I-NP
O	820	824	were	be	VBD	B-VP
O	825	832	counted	count	VBN	I-VP
O	832	833	.	.	.	O

O	834	842	Separate	Separate	JJ	B-NP
O	843	847	rats	rat	NNS	I-NP
O	848	857	underwent	undergo	VBD	B-VP
B-Cell	858	868	splenocyte	splenocyte	NN	B-NP
O	869	872	and	and	CC	I-NP
B-Cell	873	875	KC	KC	NN	I-NP
O	876	883	harvest	harvest	NN	I-NP
O	884	887	for	for	IN	B-PP
O	888	898	assessment	assessment	NN	B-NP
O	899	901	of	of	IN	B-PP
B-Cell	902	912	lymphocyte	lymphocyte	NN	B-NP
O	912	913	-	-	HYPH	B-NP
O	914	917	and	and	CC	I-NP
B-Cell	918	928	macrophage	macrophage	NN	I-NP
O	928	929	-	-	HYPH	O
O	929	937	mediated	mediate	VBN	B-NP
B-Cell	938	943	tumor	tumor	NN	I-NP
I-Cell	944	948	cell	cell	NN	I-NP
O	949	953	kill	kill	NN	I-NP
O	954	956	in	in	FW	B-ADVP
O	957	962	vitro	vitro	FW	I-ADVP
O	962	963	.	.	.	O

O	964	966	GM	GM	NNP	B-NP
O	966	967	-	-	HYPH	I-NP
O	967	970	CSF	CSF	NN	I-NP
O	971	973	or	or	CC	I-NP
O	974	976	IL	IL	NN	I-NP
O	976	977	-	-	HYPH	O
O	977	978	2	2	CD	B-NP
O	979	987	vaccines	vaccine	NNS	I-NP
O	988	990	or	or	CC	O
O	991	999	gammaIFN	gammaIFN	NN	B-NP
O	1000	1009	decreased	decrease	VBD	B-VP
B-Cancer	1010	1015	tumor	tumor	NN	B-NP
I-Cancer	1016	1023	nodules	nodule	NNS	I-NP
O	1024	1037	significantly	significantly	RB	B-ADVP
O	1038	1039	(	(	(	O
O	1039	1041	GM	GM	NNP	B-NP
O	1041	1042	-	-	HYPH	O
O	1042	1045	CSF	CSF	NNP	B-NP
O	1046	1048	13	13	CD	I-NP
O	1048	1049	+	+	SYM	B-NP
O	1049	1050	/	/	SYM	B-NP
O	1050	1051	-	-	SYM	B-VP
O	1051	1052	4	4	CD	B-NP
O	1052	1053	,	,	,	O
O	1054	1056	IL	IL	NN	B-NP
O	1056	1057	-	-	HYPH	O
O	1057	1058	2	2	CD	B-NP
O	1059	1061	14	14	CD	I-NP
O	1061	1062	+	+	SYM	B-NP
O	1062	1063	/	/	SYM	B-NP
O	1063	1064	-	-	SYM	B-VP
O	1064	1065	6	6	CD	B-NP
O	1066	1068	vs	v	NNS	I-NP
O	1068	1069	.	.	.	O
O	1070	1077	control	control	NN	B-NP
O	1078	1080	75	75	CD	I-NP
O	1080	1081	+	+	SYM	B-NP
O	1081	1082	/	/	SYM	B-NP
O	1082	1083	-	-	SYM	B-VP
O	1083	1085	24	24	CD	B-NP
O	1085	1086	,	,	,	O
O	1087	1088	P	P	NN	B-NP
O	1089	1090	<	<	SYM	B-VP
O	1091	1092	0	0	CD	B-NP
O	1092	1093	.	.	.	I-NP
O	1093	1096	001	001	CD	I-NP
O	1096	1097	)	)	)	O
O	1097	1098	.	.	.	O

O	1099	1110	Combination	Combination	NN	B-NP
O	1111	1118	therapy	therapy	NN	I-NP
O	1119	1122	was	be	VBD	B-VP
O	1123	1127	more	more	RBR	B-ADJP
O	1128	1137	effective	effective	JJ	I-ADJP
O	1137	1138	,	,	,	O
O	1139	1142	and	and	CC	O
O	1143	1153	completely	completely	RB	B-NP
O	1154	1164	eliminated	eliminate	VBN	I-NP
B-Cancer	1165	1170	tumor	tumor	NN	I-NP
O	1171	1173	in	in	IN	B-PP
O	1174	1175	4	4	CD	B-NP
O	1176	1178	of	of	IN	B-PP
O	1179	1181	12	12	CD	B-NP
O	1182	1185	IFN	IFN	NN	I-NP
O	1185	1186	-	-	HYPH	B-NP
O	1186	1188	GM	GM	NN	I-NP
O	1188	1189	-	-	HYPH	B-NP
O	1189	1192	CSF	CSF	NN	I-NP
O	1193	1196	and	and	CC	O
O	1197	1198	8	8	CD	B-NP
O	1199	1201	of	of	IN	B-PP
O	1202	1204	11	11	CD	B-NP
O	1205	1208	IFN	IFN	NN	I-NP
O	1208	1209	-	-	HYPH	B-NP
O	1209	1211	IL	IL	NN	I-NP
O	1211	1212	-	-	SYM	B-NP
O	1212	1213	2	2	CD	B-NP
O	1214	1221	animals	animal	NNS	I-NP
O	1221	1222	.	.	.	O

O	1223	1233	Additional	Additional	JJ	B-NP
O	1234	1238	rats	rat	NNS	I-NP
O	1239	1248	underwent	undergo	VBD	B-VP
O	1249	1256	partial	partial	JJ	B-NP
O	1257	1268	hepatectomy	hepatectomy	NN	I-NP
O	1268	1269	,	,	,	O
O	1270	1272	an	an	DT	B-NP
O	1273	1290	immunosuppressive	immunosuppressive	JJ	I-NP
O	1291	1300	procedure	procedure	NN	I-NP
O	1301	1306	known	know	VBN	B-VP
O	1307	1309	to	to	TO	B-VP
O	1310	1320	accelerate	accelerate	VB	I-VP
O	1321	1324	the	the	DT	B-NP
O	1325	1331	growth	growth	NN	I-NP
O	1332	1334	of	of	IN	B-PP
B-Cancer	1335	1342	hepatic	hepatic	JJ	B-NP
I-Cancer	1343	1348	tumor	tumor	NN	I-NP
O	1348	1349	,	,	,	O
O	1350	1359	following	follow	VBG	B-PP
B-Cancer	1360	1365	tumor	tumor	NN	B-NP
O	1366	1375	challenge	challenge	NN	I-NP
O	1375	1376	.	.	.	O

O	1377	1384	Therapy	Therapy	NN	B-NP
O	1385	1388	was	be	VBD	B-VP
O	1389	1396	equally	equally	RB	B-ADJP
O	1397	1406	effective	effective	JJ	I-ADJP
O	1407	1409	in	in	IN	B-PP
O	1410	1414	this	this	DT	B-NP
O	1415	1432	immunosuppressive	immunosuppressive	JJ	I-NP
O	1433	1440	setting	setting	NN	I-NP
O	1440	1441	.	.	.	O

O	1442	1453	Vaccination	Vaccination	NN	B-NP
O	1454	1456	is	be	VBZ	B-VP
O	1457	1467	associated	associate	VBN	I-VP
O	1468	1472	with	with	IN	B-PP
O	1473	1484	enhancement	enhancement	NN	B-NP
O	1485	1487	of	of	IN	B-PP
B-Cell	1488	1498	splenocyte	splenocyte	NN	B-NP
O	1498	1499	-	-	HYPH	O
O	1499	1507	mediated	mediate	VBN	B-NP
O	1508	1519	tumoricidal	tumoricidal	JJ	I-NP
O	1520	1528	activity	activity	NN	I-NP
O	1528	1529	,	,	,	O
O	1530	1537	whereas	whereas	IN	O
O	1538	1541	the	the	DT	B-NP
O	1542	1548	effect	effect	NN	I-NP
O	1549	1551	of	of	IN	B-PP
O	1552	1560	gammaIFN	gammaIFN	NN	B-NP
O	1561	1563	is	be	VBZ	B-VP
O	1564	1572	mediated	mediate	VBN	I-VP
O	1573	1575	by	by	IN	B-PP
B-Cell	1576	1578	KC	KC	NN	B-NP
O	1578	1579	.	.	.	O

O	1580	1582	GM	GM	NNP	B-NP
O	1582	1583	-	-	HYPH	I-NP
O	1583	1586	CSF	CSF	NN	I-NP
O	1587	1590	and	and	CC	I-NP
O	1591	1593	IL	IL	NN	I-NP
O	1593	1594	-	-	HYPH	B-NP
O	1594	1595	2	2	CD	I-NP
O	1596	1603	vaccine	vaccine	NN	I-NP
O	1604	1611	therapy	therapy	NN	I-NP
O	1612	1615	and	and	CC	O
O	1616	1628	pretreatment	pretreatment	NN	B-NP
O	1629	1633	with	with	IN	B-PP
O	1634	1642	gammaIFN	gammaIFN	NN	B-NP
O	1643	1652	represent	represent	VBP	B-VP
O	1653	1662	effective	effective	JJ	B-NP
O	1663	1673	strategies	strategy	NNS	I-NP
O	1674	1676	in	in	IN	B-PP
O	1677	1685	reducing	reduce	VBG	B-VP
B-Cancer	1686	1693	hepatic	hepatic	JJ	B-NP
I-Cancer	1694	1699	tumor	tumor	NN	I-NP
O	1699	1700	.	.	.	O

O	1701	1712	Combination	Combination	NN	B-NP
O	1713	1720	therapy	therapy	NN	I-NP
O	1721	1728	targets	target	VBZ	B-VP
O	1729	1733	both	both	CC	O
B-Cell	1734	1745	lymphocytes	lymphocyte	NNS	B-NP
O	1746	1749	and	and	CC	O
B-Cell	1750	1761	macrophages	macrophage	NNS	B-NP
O	1761	1762	,	,	,	O
O	1763	1766	and	and	CC	O
O	1767	1769	is	be	VBZ	B-VP
O	1770	1774	more	more	RBR	B-ADJP
O	1775	1784	effective	effective	JJ	I-ADJP
O	1785	1787	in	in	IN	B-PP
O	1788	1796	reducing	reduce	VBG	B-VP
B-Cancer	1797	1802	tumor	tumor	NN	B-NP
O	1803	1807	than	than	IN	B-PP
O	1808	1814	either	either	DT	B-NP
O	1815	1822	therapy	therapy	NN	I-NP
O	1823	1828	alone	alone	RB	B-ADVP
O	1828	1829	.	.	.	O

